Enzene Biosciences Limited, a active public limited company, was established on 28 August 2006 in Pune, Maharashtra, India. Engaging in biotechnology within the manufacturing sector, it holds CIN: U24232PN2006PLC165610. Registered under ROC Roc Pune. it is unlisted. It has an authorized capital of ₹66.00 Cr and a paid-up capital of ₹51.39 Cr.
Formerly known as Enzene Biosciences Private Limited. It upholds a compliant status. Employing 665 professional, Its leadership includes Sudha Ravi (Director), Aniruddha Singh (Additional Director), Sangeeta Kapil Jit Singh (Director). Past directors included Ravindra Yogesh Shenoy, Sudha Ravi, Sangeeta Kapil Jit Singh. It holds ₹157.37 Cr open charges and ₹137.95 Cr settled loans. Its latest AGM occurred on 22 August 2025, with the balance sheet filed on 31 March 2025. It is based at Plot No A 22, A/1/2 Chakan Industrial Area, Phase 2, Khalumbre, Chakan, Pune, Maharashtra, 410501.
U24232PN2006PLC165610
165610
28 August 2006
₹66.00 Cr
₹51.39 Cr
Roc Pune
Unlisted
Active
Explore comprehensive insights into Enzene Biosciences Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sudha Ravi | Director | 09 Feb 2017 | Current |
| Aniruddha Singh | Additional Director | 07 Mar 2025 | Current |
| Sangeeta Kapil Jit Singh | Director | 02 Aug 2022 | Current |
| Prem Venkatachalam Pavoor | Director | 30 Jan 2023 | Current |
| Himanshu Shashikant Gadgil | Ceo | 02 Feb 2022 | Current |
| Sandeep Singh | Director | 20 Oct 2011 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 01 Apr 2014 | Past |
| Pramod Abcsdd | Additional Director | 19 Aug 2022 | Past |
| Pramod Abcsdd | Additional Director | 19 Aug 2022 | Past |
| Pramod Abcsdd | Additional Director | 11 Jul 2022 | Past |
| Pramod Abcsdd | Additional Director | 21 Mar 2023 | Past |
| Pramod Abcsdd | Managing Director | 01 Apr 2014 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Enzene Biosciences Limited, for the financial year ended 2025, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
In 2024, Enzene Biosciences had a promoter holding of 99.76% and a public holding of 0.24%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹1,573,700,000.00
₹1,379,500,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Feb 2024 | Others | ₹80.00 Cr | Open |
| 31 May 2018 | Axis Bank Limited | ₹77.12 Cr | Open |
| 28 Mar 2018 | Hdfc Bank Limited | ₹2.50 M | Open |
| 16 Dec 2022 | Others | ₹43.75 Cr | Satisfied |
| 19 Apr 2017 | Axis Bank Limited | ₹45.14 Cr | Satisfied |
Explore comprehensive loan charge details -
Enzene Biosciences has a workforce of 665 employees as of Dec 25, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Enzene Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Enzene Biosciences's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity A charge registered on 16 Dec 2022 via Charge ID 100699653 with Others was fully satisfied on 18 Sep 2025. was completed.
Progress on Enzene Biosciences Limited last Annual general meeting of members was held on 22 Aug 2025 as per latest MCA records. was documented.
The activity Vikas Gupta was appointed as a Additional Director was appointed as a Additional Director on 14 Aug 2025 & has been associated with this company since 4 months 19 days . was completed.
The activity Enzene Biosciences Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Pune. was completed.
Nilesh Ambani was appointed as a Cfo was appointed as a Cfo on 28 Mar 2025 & has been associated with this company since 9 months 5 days . was recorded as a recent event.
The activity Aniruddha Singh was appointed as a Additional Director was appointed as a Additional Director on 07 Mar 2025 & has been associated with this company since 9 months 26 days . was completed.
Enzene’s new R&D facility, spanning over 75,000 square feet, is equipped with an open lab set-up that promotes cross-departmental collaboration, efficient communication, and knowledge sharing Enze.
Cetuximab is a therapeutic chimeric monoclonal antibody that is used as a targeted therapy for metastatic colorectal Cancer (mCRC) and cancer of the head and neck Pune-based Enzene Biosciences has lau.
The CIN of Enzene Biosciences Limited is U24232PN2006PLC165610.
Enzene Biosciences Limited is headquartered at Plot No A 22, A/1/2 Chakan Industrial Area, Phase 2, Khalumbre, Chakan, Pune, Maharashtra, 410501.
Enzene Biosciences Limited was incorporated on 28 August 2006.
The current directors of Enzene Biosciences Limited are
The primary industry of Enzene Biosciences Limited is Manufacturing.
Enzene Biosciences Limited is unlisted.
The authorized capital of Enzene Biosciences Limited is ₹66.00 Cr, and the paid-up capital is ₹51.39 Cr.
The compliance status of Enzene Biosciences Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX